Sensei Biotherapeutics to Join Jefferies Global Healthcare Conference

BOSTON, May 30, 2024 -- Sensei Bio, Inc. (Nasdaq: SNSE), a pioneering clinical-stage company in immuno-oncology, has announced that its President and CEO, John Celebi, will be presenting at the Jefferies Global Healthcare Conference. This event is scheduled to take place in New York, NY, on Thursday, June 6, 2024, at 8:30 a.m. ET.

For those unable to attend in person, Sensei Bio has arranged for a webcast of the presentation. This webcast will be accessible through the Investors section of the Sensei Bio website, and a replay will be available for approximately 90 days post-event. Interested parties can register for the webcast via the company's website.

About Sensei Biotherapeutics

Sensei Biotherapeutics, listed on Nasdaq under the ticker SNSE, is a clinical-stage company dedicated to the field of immuno-oncology. The company is at the forefront of creating next-generation cancer treatments. Central to Sensei Bio's innovation is its TMAb™ (Tumor Microenvironment Activated biologics) platform. This platform is utilized to develop therapeutics that can either inhibit immunosuppressive signals or enhance immunostimulatory signals specifically within the tumor microenvironment.

Key Therapeutic Candidates

1. SNS-101: The lead investigational candidate of Sensei Bio is SNS-101, a conditionally active antibody. This antibody is designed to block the VISTA checkpoint within the low pH environment of tumors. In such environments, VISTA functions as a T cell suppressor by binding to the receptor PSGL-1.

2. SNS-102: Another promising candidate is SNS-102, a conditionally active monoclonal antibody. This antibody targets VSIG-4, which plays a significant role in the suppression of immune responses in tumors.

3. SNS-103: This is a conditionally active monoclonal antibody that targets CD39, also known as ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1). CD39 is involved in the hydrolysis of extracellular nucleotides, a process that can suppress immune responses.

4. SNS-201: This therapeutic combines a CD28 agonist arm with a pH-sensitive anti-VISTA arm, creating a bispecific antibody known as VISTAxCD28. This unique combination is designed to stimulate immune responses specifically within the tumor microenvironment.

Sensei Bio’s innovative approach focuses on altering the immunosuppressive landscape of tumors to enhance the effectiveness of immune responses against cancer.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!